ClinicalTrials.Veeva

Menu

Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

COPD

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

This study is intended to evaluate treatment effectiveness of BFC compared to FSC in COPD patients new to ICS/LABA combination therapy.

Enrollment

3,000 estimated patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Continuous health plan enrollment for 12 months before and after index Rx, at least one prescription for BFC or FSC during intake period, naive to ICS/LABA therapies in year prior to first prescription claim, COPD diagnosis, aged 40 or over at time of first prescription.

Exclusion criteria

  • ICS/LABA combination during pre-index period, patients with a claim for BFC and FSC on the same day, patients diagnosed with cancer, patients with long-term OCS medication use during pre-index period.

Trial design

3,000 participants in 2 patient groups

Symbicort
Description:
BFC patients new to ICS/LABA therapies
Advair
Description:
FSC patients new to ICS/LABA therapies.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems